First reported at 416,649 shares this quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2026-09-30 | 5720591 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | New | 416,649 | +416,649 (0.0%) | 4.32% | $5,720,591 | 2026-11-13 |
Who else reported the position
60 managers reported OBSIDIAN THERAPEUTICS INC COM for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT L P | New | 5,957,103 | +5,957,103 | 0.82% | $81,791,024 | 1 qtr |
| Atlas Venture Life Science Advisors LLC | New | 4,503,149 | +4,503,149 | 9.8% | $61,828,236 | 1 qtr |
| Paradigm Biocapital Advisors LP | New | 4,155,214 | +4,155,214 | 1.13% | $57,051,088 | 1 qtr |
| Novo Holdings A S | New | 3,123,992 | +3,123,992 | 2.88% | $42,892,410 | 1 qtr |
| Trails Edge Capital Partners LP | New | 2,495,660 | +2,495,660 | 4.92% | $34,265,412 | 1 qtr |
| VANGUARD CAPITAL MANAGEMENT LLC | New | 2,441,332 | +2,441,332 | < 0.01% | $33,519,488 | 1 qtr |
| Octagon Capital Advisors LP | New | 2,414,610 | +2,414,610 | 4.42% | $33,152,595 | 1 qtr |
| TCG Crossover Management LLC | New | 2,196,138 | +2,196,138 | 0.85% | $30,152,975 | 1 qtr |
| Deep Track Capital LP | New | 2,120,050 | +2,120,050 | 0.47% | $29,108,287 | 1 qtr |
| CITADEL ADVISORS LLC | New | 1,947,843 | +1,947,843 | < 0.01% | $26,743,884 | 1 qtr |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 13, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 416,649
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.